The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Protein Expression Systems Market: Current Landscape and Future Opportunities

  • Lowest Price Guaranteed From USD 2,199

  • Published
    September 2015

  • Pages
    249

  • View Count
    3768

Example Insights

  1. Presently bacterial and mammalian cell based systems are the preferred choice for therapeutic protein expression. Bacterial systems are preferred for their low cost, high productivity and rapid results. Mammalian cells, on the other hand, have the ability to generate proteins with folding and post-translational modification identical to native endogenous protein.
  2. A number of new host systems have come into the market offering advantages such as higher protein yield, diminishing susceptibility to viral contamination and easy scale up. Among these are yeast, insect, and also certain plant based protein expression systems. Cell free systems have also gained momentum and allow direct manipulation of the chemical environment that rapidly generates significant amounts of the required protein.
  3. In addition to the well-established firms such as Agilent Technologies, Clontech, Life Technologies, Lonza, Merck Millipore, Promega Corporation and Research Corporation Technologies, several smaller companies too have developed robust proprietary expression systems. Examples (in alphabetic order) include Dyadic International, Geneva Biotech, Greenovation, iBio, Jena Bioscience, New England Biolabs, Oxford Expression Technologies, Pfenex and Scarab Genomics. 
  4. The highly lucrative biologics market presents a huge opportunity for protein expression systems. The biologics market is considered to be worth over USD 200 billion and has an increasing number of therapeutically relevant protein based molecules in the pipeline.
  5. The outlook for CMOs is highly promising. In our study, we identified over 160 biopharmaceutical CMOs (accounting for over 250 production facilities worldwide), which provide protein expression services. With around 900 biologics in the pipeline and 150 marketed products, CMOs stand to benefit tremendously from this growing trend.
  6. Technological improvements including the use of highly evolved expression elements such as designer promoters for obtaining higher translational efficiency, genome engineering to facilitate better homologous recombination and computer-controlled feeding algorithms are likely to further maximize output and yield.

Overview

Advances in genetic engineering and cloning techniques have allowed isolation and expression of heterologous and recombinant proteins for research, therapeutic and industrial uses. Large scale applications such as enzyme, antibody or vaccine production require high amounts of protein. This demands that the system producing protein must be easy to culture, allow rapid cell growth and provide good yield. Various expression systems based on the machinery of bacteria, yeast, insect or mammalian cells have been developed to cater to these demands.

Protein synthesis occurs differently in prokaryotic and eukaryotic systems; the need for post translational modifications adds a level of complexity in the latter case. Newer expression systems utilising yeast and insect cells as host are gaining momentum due to favourable culture conditions and final end products. Pichia and Sf9/Sf21 host cells have emerged as the most commonly used systems in these categories, respectively. Some plant based technologies express protein rapidly, unlike the traditional methods of production in transgenic plants. Several other expression systems based on protozoa and fungi have also demonstrated effective protein expression. In addition, cell free expression systems have also been developed and are gaining momentum in the market.

The highly lucrative biologics market presents a huge opportunity for such systems. Both large and small companies in this sector have developed proprietary recombinant protein expression techniques to carve out their own share of the multi-billion dollar market. The increasing demand for biologics has led to the involvement of various CMOs providing services in protein expression. However, there are sometechnical shortcomings in current platforms which need to be dealt with to maximize the available opportunity. The opportunity, overall, will continue to increase manifold with the approval of several new biologics and biosimilars in the coming few years.

 

Scope of the Report

The “Protein Expression Systems Market: Current Landscape and Future Opportunities” report provides an extensive study of the various expression systems commercially available for the purpose of expressing the desired proteins. Selecting an effective and reliable expression system is one of the pre-requisites for pharma companies before they start proof of concept studies for biological molecules. It is well known that a particular expression system is not suitable to express every kind of protein. As such, there are several different types of platforms available to meet the growing demand.

With an extensive pipeline of biologic drugs, protein expression systems are likely to continue to garner significant attention from the biopharmaceutical industry. The report covers various aspects such as key features of these systems, associated products, licensing and services portfolio. We have also covered specific details on CMOs manufacturing biopharmaceutical products highlighting their capabilities, geographical location, scale of operation, type of biologics being manufactured and expression systems being used.

In addition, the report highlights the future growth prospects with respect to manufacturing biological molecules. We have analyzed the overall biologics pipeline and provided specific details on some important classes such as antibody drug conjugates (ADCs) and bispecific antibodies. Further, we have highlighted the emerging opportunity presented by the ongoing development of biosimilars. For the purposes of the study, we interviewed important stakeholders to solicit their opinions around the upcoming opportunities and challenges which must be considered for a more inclusive growth. Examples of companies we interviewed include Research Corporation Technologies, iBio and Jena Bioscience.

Contents

Chapter 2  provides an executive summary of the insights captured during our research. The summary offers a high level view on the present scenario of protein expression systems market and the likely growth opportunities in the future.

Chapter 3  provides a general introduction to protein expression systems. We have briefly discussedthe basic concepts related to protein synthesis and recombinant protein expression in such systems. The chapter also covers an overview on different types of expression systems that are used for expressing protein along with their advantages and disadvantages.

Chapter 4  presents a comprehensive list of expressions systems, categorized based on the host cell in which the protein is expressed. In addition, we have also listed the expression systems being developed by various academic institutes.

Chapter 5  provides additional details on some expression systems which are relatively more popular within each specific category. Each profile highlights the key attributes such as yield, time to express protein, quality of product, associated cost, scale-up and culture requirements.

Chapter 6  presents profiles of 12 leading companies in this domain. Each company profile includes information such as company overview, financial performance, expression systems, product portfolio and licensing and partnership agreements made with other companies.

Chapter 7  elaborates on the participation of contract manufacturers in biopharmaceuticals manufacturing. This chapter includes an extensive analysis of CMOs and highlights their geographical location, manufacturing capabilities in terms of type of biologics manufactured and scale of operation, expression systems used and fermentation capacity.

Chapter 8  focuses on highlighting the opportunity areas for companies with proprietary expression systems. It provides a detailed overview on biologics currently being developed and specifically covers the pipeline of some of the important drug classes such as antibody drug conjugates and bispecific antibodies. We have also highlighted the opportunity presented by biosimilars, a key growth prospect for developers of expression systems.

Chapter 9  provides our analysis of the strengths, weaknesses, opportunities and threats in the protein expression systems market. This section captures key elements likely to influence future growth in the industry.

Chapter 10  summarizes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 11  provides three interview transcripts based on our discussion with senior stakeholders in the industry. The companies interviewed included Research Corporation Technologies, iBio and Jena Bioscience.

Chapters 12 and 13  are appendices and provide the list of companies and tabulated data for all the figures presented in the report.

Table of Contents

1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. Executive Summary
 
3. Introduction
3.1. Chapter Overview
3.2. Protein Synthesis: An Overview
3.3. Recombinant Protein Production in Expression Systems
3.4. Protein Expression Methods
3.4.1. In Vivo Protein Expression
3.4.1.1. Mammalian Protein Expression System
3.4.1.2. Bacterial Protein Expression System
3.4.1.3. Yeast Protein Expression System
3.4.1.4. Insect Protein Expression System
3.4.1.5. Plant Protein Expression System
3.4.1.6. Protozoan Protein Expression System
3.4.1.7. Algae Protein Expression System
3.4.2. In Vitro (Cell Free) Protein Expression
3.4.3. Chemical Protein Synthesis
3.5. Comparison of Commonly Used Expression Systems
 
4. Market Overview
4.1. Chapter Overview
4.2. Mammalian Expression Systems
4.3. Bacterial Expression Systems
4.4. Yeast Expression Systems
4.5. Insect Expression Systems
4.6. Plant Expression Systems
4.7. Cell-Free Expression Systems
4.8. Other Expression Systems
4.9. Universities with Proprietary Expression Systems
 
5. Expression Systems: Key Features and Products
5.1. Chapter Overview
5.2. Well-Known Mammalian Expression Systems
5.2.1. PER.C6 Technology (Crucell / Janssen)
5.2.1.1. Granted Patents
5.2.1.2. Key Features
5.2.1.3. Products
5.2.1.4. Licensing and Services
 
5.2.2. GS Gene Expression System (Lonza)
5.2.2.1. Key Features
5.2.2.2. Products
5.2.2.3. Licensing and Services
 
5.3. Well-Known Bacterial Expression Systems
5.3.1. Pfenex Technology (Pfenex)
5.3.1.1. Granted Patents
5.3.1.2. Key Features
5.3.1.3. Products
5.3.1.4. Licensing and Services
 
5.3.2. XS Bacillus Expression System (Lonza)
5.3.2.1. Key Features
5.3.2.2. Comparison of XS Expression Systems
5.3.2.3. Products
5.3.2.4. Licensing and Services
 
5.4. Well-Known Yeast Expression Systems
5.4.1. Pichia Secretory SUMOstar Expression System (LifeSensors)
5.4.1.1. Granted Patents
5.4.1.2. Key Features
5.4.1.3. Products
5.4.1.4. Licensing and Services
 
5.4.2. Pichia Glycoswitch Protein Expression System (Research Corporation Technologies)
5.4.2.1. Key Features
5.4.2.2. Products
5.4.2.3. Licensing and Services
 
5.5. Well-Known Insect Expression Systems
5.5.1. Bac-To-Bac Baculovirus Expression System (Invitrogen / Life Technologies)
5.5.1.1. Key Features
5.5.1.2. Products
5.5.1.3. Licensing and Services
 
5.5.2. Drosophila Expression System (Invitrogen / Life Technologies)
5.5.2.1. Key Features
5.5.2.2. Products
5.5.2.3. Licensing and Services
 
5.5.3. BacPAK Protein Expression Systems (Clontech)
5.5.3.1. Key Features
5.5.3.2. Products
5.5.3.3. Licensing and Services
 
5.5.4. flashBAC Expression System (Oxford Expression Technologies)
5.5.4.1. Granted Patents
5.5.4.2. Key Features
5.5.4.3. Products
5.5.4.4. Licensing and Services
 
5.6. Well-Known Plant Expression Systems
5.6.1. BryoTechnology (Greenovation Biotech)
5.6.1.1. Key Features
5.6.1.2. Products
5.6.1.3. Licensing and Services
 
5.6.2. iBioLaunch Technology (iBio)
5.6.2.1. Granted Patents
5.6.2.2. Key Features
5.6.2.3. Products
5.6.2.4. Licensing and Services
 
5.7. Well-Known Cell-Free Expression Systems
5.7.1. Xpress CF Protein Synthesis Platform (Sutro Biopharma)
5.7.1.1. Key Features
5.7.1.2. Products
5.7.1.3. Licensing and Services
 
5.7.2. TnT SP6 High-Yield Wheat Germ Protein Expression System (Promega Corporation)
5.7.2.1. Key Features
5.7.2.2. Products and Licensing
 
5.8. Other Expression Systems
5.8.1. LEXSY Protein Expression System (Jena Bioscience)
5.8.1.1. Key Features
5.8.1.2. Products
5.8.1.3. Licensing and Services
 
5.8.2. C1 Expression System (Dyadic International)
5.8.2.1. Granted Patents
5.8.2.2. Key Features
5.8.2.3. Products
5.8.2.4. Licensing and Services
 
5.8.3. Cipex System (Cilian)
5.8.3.1. Granted Patents
5.8.3.2. Key Features
5.8.3.3. Products
5.8.3.4. Licensing and Services
 
6. Company Profiles
6.1. Chapter Overview
6.2. Agilent Technologies
6.2.1. Overview
6.2.2. Financial Performance
6.2.3. Technology Platforms
6.2.3.1. PathDetect Trans Reporting Systems
6.2.3.2. PathDetect Cis-Reporting Systems
6.2.3.3. LacSwitch II Inducible Mammalian Expression System
6.2.4. Product Portfolio
 
6.3. Clontech
6.3.1. Overview
6.3.2. Financial Performance
6.3.3. Technical Platforms
6.3.3.1. HAT Protein Expression and Purification System
6.3.3.2. pET Expression System
6.3.3.3. Baculovirus Expression Systems (BacPAK Method)
6.3.4. Product Portfolio
 
6.4. Geneva Biotech
6.4.1. Technology Platforms
6.4.1.1. MultiBac™ Expression System
6.4.1.2. SweetBac™ Expression System
6.4.1.3. VLP Factory™
6.4.1.4. iBac™
6.4.1.5. ManuBac™
6.4.1.6. MultiBacMam™
6.4.1.7. MultiMam™ Transient
6.4.1.8. MultiMam™ Stable
6.4.1.9. Multicoli™
6.4.2. Product Portfolio
6.4.3. Licensing and Partnerships
 
6.5. Life Technologies / Thermo Fisher
6.5.1. Overview
6.5.2. Financial Performance
6.5.3. Technology Platforms
6.5.3.1. Geneart® Algae Expression and Engineering Kits
6.5.3.2. Scalable Transient Protein Expression Systems
6.5.3.3. Viral Gene Delivery for Protein Expression (Viral Power™)
6.5.3.4. Membrane Pro Expression Systems
6.5.3.5. T-REx Systems
6.5.3.6. Champion™ Pet Expression Systems
6.5.3.7. Bac-To-Bac® Baculovirus Expression System
6.5.3.8. Bac-To-Bac® HBM TOPO® Secreted Expression System
6.5.3.9. BaculoDirect™ Baculovirus Expression System
6.5.3.10. PichiaPinkTM Yeast Expression Systems
6.5.3.11. Pichia Expression Systems
6.5.3.12. MembraneMaxTM Protein Expression Kits
6.5.3.13. Meddes Drosophila Expression Systems
6.5.4. Product Portfolio
6.5.5. Licensing and Partnerships
 
6.6. Life Sensors
6.6.1. Overview
6.6.2. Technology Platforms
6.6.2.1. SUMO E.coli Expression Systems
6.6.2.2. SUMO Mammalian Expression Systems
6.6.2.3. SUMO Insect Expression Systems
6.6.2.4. SUMO Yeast Expression Systems
6.6.3. Product Portfolio
6.6.4. Licensing and Partnerships
 
6.7. Lonza
6.7.1. Overview
6.7.2. Financial Performance
6.7.3. Technology Platforms
6.7.3.1. GS Gene Expression System
6.7.3.2. GS Xceed Gene Expression System
6.7.3.3. XS E.coli Expression Systems
6.7.3.4. XS Pichia Expression Systems
6.7.3.5. XS Bacillus Expression Systems
6.7.4. Product Portfolio
6.7.5. Licensing and Partnerships
 
6.8. Merck Millipore
6.8.1. Overview
6.8.2. Financial Performance
6.8.3. Technology Platforms
6.8.3.1. Insect direct® System
6.8.3.2. UCOE Expression Technology
6.8.3.3. pET Expression System
6.8.4. Product Portfolio
6.8.5. Licensing and Partnerships
 
6.9. New England Biolabs
6.9.1. Overview
6.9.2. Technology Platforms
6.9.2.1. Gene Expression System
6.9.2.2. Yeast Protein Expression Kit
6.9.2.3. Cell-Free Expression Systems
6.9.3. Product Portfolio
6.9.4. Licensing and Partnerships
 
6.10. Oxford Expression Technologies
6.10.1. Overview
6.10.2. Technology Platforms
6.10.2.1. flashBAC Expression Systems
6.10.2.2. flashBAC Ultra Baculovirus Expression System
6.10.2.3. BacMam Expression Systems
6.10.3. Product Portfolio
6.10.4. Licensing and Partnerships
6.11. Pfenex (Dow Pharma)
6.11.1. Overview
6.11.2. Financial Performance
6.11.3. Technology Platforms
6.11.4. Product Portfolio
6.11.5. Licensing and Partnerships
 
6.12. Promega Corporation
6.12.1. Overview
6.12.2. Financial Performance
6.12.3. Technology Platforms
6.12.3.1. TNT® Quick Systems
6.12.3.2. TNT® T7 Insect Cell Extract Protein Expression System
6.12.3.3. TNT® SP6 High-Yield Protein Expression System
6.12.3.4. Regulated Mammalian Expression System
6.12.3.5. S30 T7 High-Yield Protein Expression System
6.12.4. Product Portfolio
 
6.13. Research Corporation Technology
6.13.1. Overview
6.13.2. Technology Platforms
6.13.2.1. Pichia Classic Protein Expression System
6.13.2.2. Pichia Glycoswitch Protein Expression System
6.13.2.3. Endotoxin-Free Clearcoli Expression System
6.13.3. Product Portfolio
6.13.4. Licensing and Partnerships
 
7. CMO Services
7.1. Chapter Overview
7.2. Biopharmaceutical CMOs: Regional Analysis
7.3. Biopharmaceutical CMOs: Analysis by Scale of Operation
7.4. Biopharmaceutical CMOs: Capability Analysis
7.4.1. Distribution by Type of Biologic Molecule
7.4.2. Distribution by Expression Systems
7.5. Biopharmaceutical CMOs: Type of Bioreactors
7.6. Roots Analysis Perspective
 
8. Opportunity Analysis
8.1. Chapter Overview
8.2. Marketed Biologics
8.3. Pipeline Biologics
8.3.1. Case-In-Point: Antibody Drug Conjugates
8.3.1.1. Development Pipeline
8.3.1.2. Pipeline Analysis
8.3.2. Case-In-Point: Bispecific Antibodies
8.3.2.1. Drugs Indicated for Oncological Diseases
8.3.2.2. Drugs Indicated for Non-Oncological Diseases
8.3.2.3. Drugs in Preclinical Trials
8.3.2.4. Pipeline Analysis
8.3.3. Case-In-Point: Subcutaneous Biologics
8.3.3.1. Pipeline Analysis
8.3.3.1.1. Distribution by Type of Molecule
8.3.3.1.2. Distribution by Phase of Development
8.3.3.1.3. Distribution by Indication
8.4. Biosimilars
8.4.1. Biosimilars: Distribution by Geography
8.4.2. Biosimilars: Distribution by Phase of Development
8.4.3. Biosimilars: Distribution by Product Category
8.5. Roots Analysis Perspective
 
9. SWOT Analysis
9.1. Overview
9.2. Strengths
9.3. Weaknesses
9.4. Opportunities
9.5. Threats
 
10. Interview Transcripts
10.1. Chapter Overview
10.2. Interview 1: Dr. Reinhard Breitling, Head of LEXSY Division, Jena Bioscience
10.3. Interview 2: Dr. Terence E Ryan, Senior Vice President and Chief Scientific Officer, iBio
10.4. Interview 3: Dr. Kurt R. Gehlsen, Vice President and Chief Scientific Officer, Research Corporation Technologies
 
11. Conclusion
11.1. Protein Expression: A Well Established Process for Producing Recombinant Proteins
11.2. Mammalian and Bacterial Systems are Widely Popular; New Systems are Gaining Attention
11.3. Biologics: A High Opportunity Market
11.4. Highly Promising Outlook for CMOs
11.5. Concluding Remarks
 
12. Appendix 1: Tabulated Data
 
13. Appendix 2: List of Companies and Organizations

List of Figures

Figure 3.1 Protein Synthesis: An Overview
Figure 3.2 Recombinant Protein Expression Process
Figure 3.3 Types of Expression Systems
Figure 4.1 Expression Systems: Distribution by Type of Host
Figure 6.1 Agilent Technologies: Historical Sales (USD Billion), 2010-2014
Figure 6.2 Agilent Technologies: Sales by Business Segments (USD Billion), 2014
Figure 6.3 Takara Bio: Historical Sales (JPY Billion), 2010-2014
Figure 6.4 Takara Bio: Sales by Business Segments (JPY Billion), 2014
Figure 6.5 Thermo Fisher: Historical Sales (USD Billion), 2010-2014
Figure 6.6 Lonza: Historical Sales (CHF Billion), 2011- 2014
Figure 6.7 Merck Millipore: Historical Sales (EUR Billion), 2010-2014
Figure 6.8 Pfenex: Historical Sales (USD Million), 2012-2014
Figure 6.9 Promega: Historical Sales (USD Million), 2008 - 2012
Figure 7.1 Biopharmaceutical CMOs: Geographical Locations
Figure 7.2 Biopharmaceutical CMOs: Distribution by Regions
Figure 7.3 Biopharmaceutical CMOs: Distribution by Scale of Operation
Figure 7.4 Biopharmaceutical CMOs: Distribution by Type of Biologic Molecule
Figure 7.5 Biopharmaceutical CMOs: Distribution by Expression Systems
Figure 7.6 Single Use Bioreactors: Advantages and Disadvantages
Figure 8.1 Approved Biologics: Distribution by Type of Host Cell
Figure 8.2 Pipeline Biologics: Distribution by Type of Molecule
Figure 8.3 Antibody Drug Conjugates Pipeline: Distribution by Phase of Development
Figure 8.4 Bispecific Antibodies Pipeline: Distribution by Phase of Development
Figure 8.5 Subcutaneous Biologics Pipeline: Distribution by Type of Molecule
Figure 8.6 Subcutaneous Biologics Pipeline: Distribution by Phase of Development
Figure 8.7 Subcutaneous Biologics Pipeline: Leading Indications / Therapeutic Areas
Figure 8.8 Biosimilars: Distribution by Geography
Figure 8.9 Biosimilars: Distribution by Phase of Development
Figure 8.10 Biosimilars: Distribution by Product Category
Figure 11.1 Pipeline Biologics: Distribution by Type of Molecule
Figure 11.2 Biopharmaceutical CMOs: Distribution by Expression Systems

List of Tables

Table 3.1 Comparison of Expression Systems
Table 4.1 List of Mammalian Expression Systems
Table 4.2 List of Bacterial Expression Systems
Table 4.3 List of Yeast Expression Systems
Table 4.4 List of Insect Expression Systems
Table 4.5 List of Plant Expression Systems
Table 4.6 List of Cell-Free Expression Systems
Table 4.7 List of Other Expression Systems
Table 4.8 List of Universities / Academia with Expression Systems
Table 5.1 PER.C6 Cell Line Technology: Product Portfolio
Table 5.2 Pfenex Technology: Product Portfolio
Table 5.3 Pfenex Technology: Partnerships/Deals (2012-2015)
Table 5.4 XS Expression Systems: Comparison
Table 5.5 Bac-to-Bac Baculovirus Expression System: Product Portfolio
Table 5.6 Drosophila Expression System: Product Portfolio
Table 5.7 Drosophila Expression System: Expressed Products
Table 5.8 BacPAK Protein Expression Kits
Table 5.9 flashBAC Expression Vector System: Expression Kits
Table 5.10 flashBAC Expression System: Licensing Deals (2012-2015)
Table 5.11 BryoTechnology: Product Portfolio
Table 5.12 iBioLaunch Technology: Product Portfolio
Table 5.13 iBioLaunch Technology: Partnerships/Deals (2012-2015)
Table 5.14 Xpress CF Protein Synthesis Platform: Product Portfolio
Table 5.15 Xpress CF Technology: Licensing Deals (2012-2015)
Table 5.16 LEXSY Expression Kits
Table 6.1 Agilent Technologies: Product Portfolio
Table 6.2 Clontech Laboratories: Products of Expression Systems
Table 6.3 Geneva Biotech: Product Portfolio
Table 6.4 Life Technologies: Product Portfolio
Table 6.5 Lifesensors: Product Portfolio
Table 6.6 Lonza: Product Portfolio
Table 6.8 Merck Millipore: Product Portfolio
Table 6.9 New England Biolabs: Product Portfolio
Table 6.10 Oxford Expression Technologies: Product Portfolio
Table 6.11 Oxford Expression Technologies: Partnerships
Table 6.12 Pfenex Technology: Product Portfolio
Table 6.13 Pfenex Technology: Partnerships (2012-2015)
Table 6.14 Promega Corporation: Product Portfolio
Table 6.15 Research Corporation Technology: Product Portfolio
Table 7.1 Biopharmaceutical CMOs: Scale of Operation
Table 7.2 Biopharmaceutical CMOs: Type of Biologics
Table 7.3 Biopharmaceutical CMOs: Type of Expression Systems
Table 7.4 Biopharmaceutical CMOs: Type of Bioreactor
Table 8.1 Marketed Biologics
Table 8.2 Antibody Drug Conjugates: Clinical Development Pipeline
Table 8.3 Antibody Drug Conjugates: Preclinical / Discovery Development Pipeline
Table 8.4 Bispecific Antibodies: Clinical Development Pipeline (Oncology)
Table 8.5 Bispecific Antibodies: Clinical Development Pipeline (Non-Oncology)
Table 8.6 Bispecific Antibodies: Preclinical / Discovery Development Pipeline
Table 8.6 Subcutaneous Biologics: Development Pipeline
Table 8.7 Biosimilars: Development Pipeline
Table 9.1 SWOT Analysis
Table 9.2 Protein Expression Systems for Co-Expression
Table 12.1 Expression Systems: Distribution by Type of Host
Table 12.2 Agilent Technologies: Historical Sales (USD Billion), 2010-2014
Table 12.3 Agilent Technologies: Sales of Business Segments (USD Billion), 2014
Table 12.4 Takara Bio: Historical Sales (JPY Billion), 2010-2014
Table 12.5 Takara Bio: Sales of Business Segments (JPY Billion), 2014
Table 12.6 Thermo Fisher: Historical Sales (USD Billion), 2010-2014
Table 12.7 Lonza: Historical Sales (CHF Billion), 2011- 2014
Table 12.8 Merck Millipore: Historical Sales (EUR Billion), 2010-2014
Table 12.9 Pfenex: Historical Sales (USD Million), 2012- 2014
Table 12.10 Promega: Historical Sales (USD Million), 2008-2012
Table 12.11 Approved Biologics: Distribution by Type of Host Cell
Table 12.12 Pipeline Biologics: Distribution by Type of Molecule
Table 12.13 ADCs Pipeline: Distribution by Phase of Development
Table 12.14 Bispecific Antibodies Pipeline: Distribution by Phase of Development
Table 12.15 Subcutaneous Biologics Pipeline: Distribution by Type of Molecule
Table 12.16 Subcutaneous Biologics Pipeline: Distribution by Phase of Development
Table 12.17 Subcutaneous Biologics Pipeline: Leading Indications / Therapeutic Areas
Table 12.18 Biosimilars: Distribution by Phase of Development

Listed Companies

The following companies and organizations have been mentioned in the report:

  1. 3P Biopharmaceuticals
  2. 5 PRIME
  3. AAIPharma Services
  4. AbbVie
  5. AbGenomics
  6. Abnova
  7. AdAlta
  8. ADC Therapeutics
  9. Aeras
  10. Affinicon
  11. Affinity Life Sciences
  12. Agilent Technologies
  13. Ajinomoto Althea
  14. Aldevron
  15. Allele Biotechnology
  16. Alliance Medical Products (Siegfried)
  17. Alpax Pharmaceuticals
  18. Ambrx
  19. AMEGA Biotech
  20. AMYRA Biotech
  21. Apotex Fermentation
  22. Aragen Bioscience
  23. Artes Biotechnology
  24. Asahi Glass Co.
  25. Astellas
  26. AthenaES
  27. AutekBio
  28. Avecia
  29. Avesta Biotherapeutics and Research
  30. Avid Bioservices
  31. Batavia Bioservices
  32. Bavarian Nordic
  33. Baxter BioPharma Solutions
  34. Bayer Healthcare
  35. BD Biosciences
  36. Bharat Biotech
  37. BIBITEC
  38. Binex Co.
  39. Bio Elpida
  40. BioCision
  41. Bio-Concept
  42. BioConnection
  43. BioConvergence
  44. BioGenomics
  45. BioGrammatics
  46. Bioinformatics
  47. BioIngenium
  48. BioMARC
  49. Biomay
  50. BIOMEVA
  51. Bioneer
  52. Frederick National Laboratory for Cancer Research (FNLCR)
  53. BioPharmaceuticals Australia
  54. Bio-Rad Laboratories
  55. BioReliance
  56. BioSavita
  57. BioSynergy
  58. Biotechnique
  59. Biotechpharma
  60. Biotest
  61. BioVectra
  62. Biovest International
  63. Biovian
  64. Biovolutions
  65. BioXcellence (Boehringer Ingelheim)
  66. Bristol Myers Squibb
  67. BroadOak Capital Partners
  68. Cantab Biopharmaceuticals
  69. Catalent
  70. Catalyst biosciences
  71. Cellca
  72. Celldex Therapeutics
  73. CellFree Sciences
  74. Celgene
  75. Celonic
  76. Center for Biocatalysis and Bioprocessing, The University of Iowa
  77. Cerbios-Pharma
  78. CEVEC Pharmaceuticals
  79. ChemPartner
  80. Cilian
  81. Clontech (a Takara Bio Company)
  82. CMC Biologics
  83. Cobra Biologics
  84. Cognate BioServices
  85. Concord Biotech
  86. Cook Pharmica
  87. Creative Biolabs
  88. Crucell
  89. Cytovance Biologics
  90. Dalton Pharma Services
  91. Development Center for Biotechnology, Taiwan
  92. DisperSol technologies
  93. DM BIO DONG-A meiji
  94. Dow Pharma
  95. Dyadic International
  96. Emergent BioSolutions
  97. Enteris BioPharma
  98. Esperance Pharmaceuticals
  99. EUCODIS Bioscience
  100. Eurogentec
  101. Florida Biologix
  102. FormATECH
  103. Formation Biologics
  104. FUJIFILM Diosynth Biotechnologies
  105. Fujirebio Europe
  106. Gala Biotech (Catalent subsidiary)
  107. GeneCopoeia
  108. Geneva Biotech
  109. Genhelix (mAbxience group)
  110. Genmab
  111. GlaxoSmithKline Biopharmaceuticals
  112. Glide Pharma
  113. Glycotope Group
  114. Gold Standard Diagnostics
  115. Goodwin Biotechnology
  116. Grand River Aseptic Manufacturing
  117. GREENOVATION
  118. GTP Technology
  119. HALIX
  120. Hisun Pharmaceuticals USA
  121. Hong Kong Institute of Biotechnology
  122. Hospira One 2 One
  123. iBIO
  124. IDT Biologika
  125. Inno Biologics
  126. Innovent Biologics
  127. Intas Pharmaceuticals
  128. Integrity Bio
  129. Intrexon
  130. Irvine Pharmaceutical Services
  131. Jena Bioscience
  132. Jenrin Discovery
  133. KABS Pharmaceutic Services
  134. Kairos Therapeutics
  135. KBI BioPharma
  136. Kemwell Biopharma
  137. Kentucky BioProcessing
  138. Lampire Biological Laboratories
  139. Leinco Technologies
  140. LFB Biomanufacturing
  141. Life Technologies
  142. LifeSensors
  143. Lonza
  144. Lucigen
  145. Lyophilization Services of New England.
  146. Mabion
  147. Maine Biotechnology Services
  148. MassBiologics
  149. MBI International
  150. Medicago
  151. Memorial Sloan-Kettering Cancer centre
  152. Menarini Biotech
  153. Merck KGaA
  154. Merck Millipore
  155. Merck Serono
  156. Meridian Life Science
  157. Miltenyi Biotec
  158. MoBiTec
  159. Mycenax Biotech
  160. Neuland Laboratories
  161. New England Biolabs
  162. Nextar Chempharma Solutions
  163. Norwegian Institute of Public Health
  164. Nova Laboratories
  165. Novasep
  166. Novozymes
  167. OctoPlus
  168. Omnia Biologics
  169. Orflo Technologies
  170. OsoBio (AMRI)
  171. Oxford Expression Technologies
  172. PacificGMP
  173. PATH
  174. Paragon Bioservices
  175. Patheon (unit of DPx Holdings)
  176. Pfizer CentreSource
  177. PharmaSynth
  178. Pharmedartis
  179. Phyton Biotech
  180. Piramal Pharma Solutions
  181. Plant BioScience
  182. Plasmid Factory
  183. Polymun Scientific
  184. Premas Biotech
  185. ProBioGen
  186. ProteoNic
  187. Progenitor Cell Therapy
  188. ProMab Biotechnologies
  189. Promega Corporation
  190. Protalix Biotherapeutics
  191. Provantage Biodevelopment Center
  192. PX’Therapeutics
  193. PYRAMID Laboratories
  194. QuaDPharma
  195. Reliance Life Sciences
  196. Rentschler Biotechnologie
  197. Research Corporation Technologies
  198. Rhein Biotech
  199. Richter-Helm BioTec
  200. RiNA
  201. SAFC
  202. Samsung BioLogics
  203. Sandoz
  204. Sanofi Pasteur
  205. Sanofi CEPiA
  206. Sanquin Pharmaceutical Services
  207. Scarab Genomics
  208. Scil Proteins
  209. Shasun
  210. SICOR Biotech  (Teva)
  211. Sigma-Aldrich Corporation
  212. Sinocelltech
  213. Statens Serum Institut
  214. Strides Arcolab
  215. Sutro Biopharma
  216. Symbiosis Pharmaceutical Services
  217. SynCo Bio Partners
  218. Syngene (Subsidiary of Biocon)
  219. Synthon
  220. Sypharma
  221. Tetragenetics
  222. Teva Pharmaceuticals
  223. Therapure Biopharma
  224. Thermo Fisher Scientific
  225. Toyobo Biologics
  226. Trenzyme
  227. University of California, San Francisco (UCSF)
  228. University of Nebraska
  229. Valneva
  230. Vetter Pharma International
  231. VGXI
  232. Vibalogics
  233. Vista Biologicals Corp.
  234. Vivalis SA
  235. VTU Technology
  236. Wacker Biotech
  237. Waisman Biomanufacturing
  238. Wockhardt
  239. WuXi AppTec
  240. Xbrane Bioscience
  241. Xcelience
  242. Zhejiang Medicine Co.
  243. Zymeworks

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 2,199

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com